OS of patients based on 2017 and 2022 ELN classifications for all treatments and IC treatment subgroup. (A-B) OS based on ELN 2017 (A) and ELN 2022 (B) criteria in all treated patients. Although both criteria appropriately identified patients with favorable-risk AML, the 2022 criteria more effectively stratified survival between patients with intermediate and adverse-risk AML. (C-D) Similar findings were observed when limited to the population of patients treated with intensive chemotherapy, in which the ELN guidelines are most well validated.